Treatment of locally advanced non-small cell lung cancer.
Approximately one third of non-small cell lung cancer (NSCLC) patients will present with locally advanced, stage III disease. With the use of pretreatment positron emission testing and mediastinal lymph node sampling, classifying stage III NSCLC has become more involved and treatment strategies have shifted from single modality thoracic radiation to combined chemoradiotherapy. This article reviews evidence-based strategies in the treatment of locally advanced NSCLC and presents new efforts for improving the poor prognosis of this disease by incorporating novel chemotherapy and biologic based regimens.
Fidler
Mary Jo
MJ
Section of Medical Oncology, Rush University Medical Center, Chicago, IL 60612, USA. mary_fidler@rush.edu
Kim
Anthony W
AW
Zusag
Thomas
T
Bonomi
Philip
P
D000971:Antineoplastic Combined Chemotherapy Protocols; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000379:methods